Crizotinib is currently thought to exert its effects through modulation of the growth, migration, and invasion of malignant cells.<ref name="TrialNCT00585195"/><ref name='Christensen_2007'>{{cite journal |vauthors=Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G | title = Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma | journal = Mol. Cancer Ther. | volume = 6 | issue = 12 Pt 1 | pages = 3314–22 | year = 2007 | pmid = 18089725 | doi = 10.1158/1535-7163.MCT-07-0365 }}</ref>  Other studies suggest that crizotinib might also act via inhibition of [[angiogenesis]] in malignant tumors.<ref name = "Zou_2007">{{cite journal |vauthors=Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG | title = An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms | journal = Cancer Res. | volume = 67 | issue = 9 | pages = 4408–17 | year = 2007 | pmid = 17483355 | doi = 10.1158/0008-5472.CAN-06-4443 }}</ref>
